Biosense Webster receives CE mark for VARIPULSE PFA Platform
March 4, 2024
Biosense Webster, a cardiac arrhythmia treatment specialist and part of Johnson & Johnson MedTech, has received CE mark approval for the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF) using pulsed field ablation (PFA).